The Medical Letter on Drugs and Therapeutics
Naloxone (Narcan) Nasal Spray for Opioid Overdose
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The recent increase in deaths due to overdose of heroin and prescription opioids in the US has renewed interest in the opioid antagonist naloxone, particularly in making it available to first responders and to relatives and close friends of persons using heroin or taking prescription opioids. IV or IM administration by healthcare professionals is preferred, but peripheral venous access may be difficult to obtain in IV drug abusers, and exposure to their blood may be hazardous.

The FDA has now approved an intranasal formulation of naloxone (Narcan nasal spray – Adapt) for emergency treatment of opioid overdose. It is the first nasal spray to be approved for this indication, but naloxone solution has been administered intranasally off-label, using a mucosal atomizer device.1 The drug also recently became available in an auto-injector formulation (Evzio) for IM or SC ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Naloxone (Narcan) Nasal Spray for Opioid Overdose
Article code: 1485a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian